Navigation Links
Psyadon Announces Positive Interim Analysis of Phase 2 Study of Ecopipam for the Treatment of Tourette Syndrome
Date:7/24/2012

GERMANTOWN, Md., July 24, 2012 /PRNewswire/ -- Psyadon Pharmaceuticals, Inc. announced today that its Phase 2 study of ecopipam in patients with Tourette Syndrome was stopped early when a planned interim analysis revealed a statistically significant reduction in the severity of the patients' tic symptoms. This decision was supported by both the independent Drug Safety and Monitoring Committee overseeing the study and by the external Research Committee established as part of Psyadon's partnership with the Tourette Syndrome Association (TSA) - the nation's largest patient advocacy group for this disorder.

"Stopping this study early because of positive results is an important development for Psyadon and hopefully for patients with Tourette Syndrome," said Richard Chipkin, Ph.D., president and chief executive officer of Psyadon. "We are eager to move ecopipam into the next stages of clinical development."

Donald Gilbert, M.D., the study's principal investigator and professor and director of the Movement Disorder and Tourette Syndrome clinics at Cincinnati Children's Hospital Medical Center said "I am encouraged by the results of this study. I believe a lot of families are looking for new treatment options and current therapies have serious side effects. Although more investigation is needed, ecopipam may represent a safer, more effective choice."

Kevin McNaught, Ph.D., vice president for medical and scientific programs at the TSA added "The TSA is proud to have helped fund this study. There haven't been any new treatments for Tourette Syndrome approved by the FDA in over twenty years. Should ecopipam's efficacy be confirmed in future trials, it would be a welcome addition to the resources available to these patients."

About the Study

This Phase 2 study called 'Ecopipam Treatment of Tourette's Syndrome (PSY301)', was a multicenter, open-label, nonrandomized study conducted to assess the ac
'/>"/>

SOURCE Psyadon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Egalet Announces Issuance of U.S. Patent
2. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
3. Sancilio and Company Announces New Directors
4. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
5. K-V Pharmaceutical Company Announces Additional Notification from NYSE Regarding Listing Criteria
6. Kraton Performance Polymers, Inc. Announces Second Quarter 2012 Earnings Release Conference Call and Webcast and 2012 Investor Day and Webcast
7. Rochester Medical Announces Third Quarter 2012 Earnings Conference Call Friday, July 27, 2012
8. Hologic Announces Pricing Of Financing In Connection With Acquisition Of Gen-Probe
9. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. China Health Resource Announces Go Global Initiative For New Product Introductions
11. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- Children aren,t the only segment of our ... disease. The Centers for Disease Control and Prevention ... many adults are not following this advice. ... and the American Lung Association in partnership with ... disease, to talk with their health care provider ...
(Date:8/20/2014)... , Aug. 20, 2014 ... report is available in its catalogue: ... for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, ... http://www.reportlinker.com/p0652514/Wireless-Opportunities-in-Healthcare-The-Market-for-Bluetooth-RFID-Zigbee-UWB-WWAN-WMAN-WLAN-and-other-technologies.html Kalorama Information,s ... Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN ...
(Date:8/20/2014)... 2014  Decision Resources Group finds that ... device market will expand through 2023 as ... fibrillation (AF). The increasing acceptance of ablation ... will spur adoption of premium-priced products designed ... loop diagnostic catheters, cryoablation catheters and contact ...
Breaking Medicine Technology:American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 13Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 14Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 15Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 16Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... April 18, 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... and Drug Administration (FDA) has accepted for review the ... the treatment of the neovascular form of age-related macular ... request for priority review of its BLA.  A Priority ...
... PDL BioPharma, Inc. (PDL) (NASDAQ: ... meeting of stockholders on Wednesday, June 22, 2011 at 10:00 a.m. ... The meeting will take place at the Hyatt Regency Hotel in ... PDL pioneered the humanization of monoclonal antibodies and, ...
Cached Medicine Technology:FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 2FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 3
(Date:8/20/2014)... In less than a week the airwaves ... to fight muscle related disease. Helping the huge telethon ... brands through their cause-related marketing heft. With their help ... nearly $60 million. , But for small self-serve business ... cause-related marketing remains decidedly local and, although the money ...
(Date:8/20/2014)... 21, 2014 Recently, UWDress.com, the distinguished ... selection of birthday party dresses for girls . ... are well-designed and exquisitely handmade by experienced specialists. Now, ... percent off. , The company’s new items come in ... short knee length frocks, long elegant backless gowns and ...
(Date:8/20/2014)... Jacksonville, FL (PRWEB) August 20, 2014 ... Continuing Education Standards (IBCCES) , an organization recognizing ... area of autism, has announced that with a ... in working with people on the Autism Spectrum ... commitment to providing quality care. This, in turn, ...
(Date:8/20/2014)... 2014 (HealthDay News) -- A group representing U.S. obstetricians ... flu shot. According to the American College of ... years have upheld the safety and effectiveness of flu ... infectious and can be particularly dangerous to pregnant women, ... complications," Dr. Laura Riley, chair of the college,s Immunization ...
(Date:8/20/2014)... the immune system is defective in people suffering from irritable ... ongoing issues with pain. , The research the first ... to explain why some painkillers may not offer satisfactory relief ... 10% of the community. There are different forms of ... often has the greatest impact on sufferers, quality of life. ...
Breaking Medicine News(10 mins):Health News:On Eve of Big Telethon, Froyo Businesses Participate but Also Go Their Own -- Local Way 2Health News:On Eve of Big Telethon, Froyo Businesses Participate but Also Go Their Own -- Local Way 3Health News:Cheap Birthday Party Dresses for Girls Now Available at UWDress.com 2Health News:National Autism Certificate Credentialing Board IBCCES Increases Job Placement Opportunities for Those Dedicated to Working Within the Autism Spectrum 2Health News:National Autism Certificate Credentialing Board IBCCES Increases Job Placement Opportunities for Those Dedicated to Working Within the Autism Spectrum 3Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Pain treatments less effective for those with irritable bowel 2
... leader in soft-cloth nasal CPAP masks, announces the new Zzzephyr ... comfortably over the patient,s nose. The lightweight seal reduces air ... Obstructive Sleep Apnea patients. , The SleepWeaver ADVANCE with Zzzephyr ... at the Medtrade Fall Show in Atlanta, Georgia, October 12 ...
... Calif., Oct. 26 Ingenuity Systems, the leading provider ... it has developed a new gene expression workflow with ... and the Applied Biosystems SOLiD(TM) System and TaqMan® Gene ... for researchers to analyze and understand the transcriptome of ...
... particularly younger women, experienced larger improvements in hospital mortality ... study published in the Oct. 26, 2009 issue of ... decade several studies showed that younger women, but not ... hospital after MI than age-matched men. A team of ...
... The topical application ... and absorption throughout the surface of the skin and scalp. A new line of naturally ... for a variety of topical conditions affecting the skin, scalp and feet. , ... Schenectady, NY (PRWEB) October 26, 2009 -- ...
... ... announce it has been honored with the BayCare Quality Award for the team,s project ... patient successes including follow through on outpatient office visits, 30-day readmission rates, and A1c ... ...
... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... modification and Lorcaserin for Overweight and Obesity Management) ... weight loss, improved markers of cardiovascular risk and ... or suicidal ideation. Additional subgroup analyses showed that ...
Cached Medicine News:Health News:Circadiance Launches NEW Zzzephyr Seal(TM) for Its SleepWeaver(TM) ADVANCE Mask - Now Available in Three Colors 2Health News:Ingenuity Systems Enhances Workflow for Experimental Transcriptome Analysis in Single Cells 2Health News:Survival after heart attack improves in younger women 2Health News:Caffeinated Cayenne Pepper Body Sprays Relieve Common Skin and Scalp Problems 2Health News:Caffeinated Cayenne Pepper Body Sprays Relieve Common Skin and Scalp Problems 3Health News:IN Compass Health's Hospitalist Team at Morton Plant wins first BayCare Quality Award 2Health News:IN Compass Health's Hospitalist Team at Morton Plant wins first BayCare Quality Award 3Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 2Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 3Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 4Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 5Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 6Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 7Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 8
MBP's equivalent to the "Universal Yellow" tip, this 200 ul tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
... easy way to order tips. Each box contains ... D10mL, which contains 200 tips (4 bags of ... Packs of 200 tips per pack. Bulk Packs ... easily be opened for quick access to Gilsons ...
10 L, Bulk Recommended for 2, 5, 10 L pipettes....
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
Medicine Products: